The Pharmacogenomics Group is directed by Dr. Zhan Zhou, Associate Professor at College of Pharmaceutical Sciences, Zhejiang University. Dr. Zhou was graduated as a Ph.D. from Zhejiang University, majoring in Biochemistry and Molecular Biology. He also studied at the University of Texas at San Antonio as a joint-PhD student. After graduation, he worked as a postdoctoral fellow at the School of Life Sciences, Fudan University. He joined the College of Pharmaceutical Sciences, Zhejiang University in 2014 and is currently Associate Director of the Department of Pharmacy, and also Associate Director of the Institute of Drug Metabolism and Pharmaceutical Analysis. The main research interests of our group are focused on the pharmacogenomics and precision medicine. With the help of big data of multi-omics and artificial intelligence technology, we would like to identify cancer driver genes and mutations, screen tumor-specific neoantigen targets, and design neoantigen-targeting drugs using antibodies and immunotherapies. At present, our group has published more than 50 SCI papers, in the academic journals such as Nat Commun, Mol Biol Evol, Brief Bioinform and Genom Proteom Bioinform. We also have developed several bioinforamtics tools and databases, such as DeepHLApan, TSNAD, TSNAdb, COVIEdb, CandrisDB.
Our Software & Database
detect somatic mutation and predict potential tumor-specific mutated antigens.
a novel software based on the RNNs which can predict peptide binding affinity with HLA alleles pan-specifically.
the database about Tumor-Specific NeoAntigens.
a web browser about predicted driver sites and corresponding driver genes with statistical parameters.
predict all the potential B/T cell epitopes for 2019-nCoV, RaTG13-CoV, SARS-CoV and MERS-CoV.
(●'◡'●)ﾉ This website has running： 0 d 0 h 55 min 52 s